← Browse by Condition
Medical Condition
lung non small cell carcinoma
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2, Phase 3, Phase 1
ClinicalMetric tracks all active clinical trials for lung non small cell carcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — lung non small cell carcinoma Clinical Trials
How many clinical trials are currently recruiting for lung non small cell carcinoma?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for lung non small cell carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for lung non small cell carcinoma?
lung non small cell carcinoma research spans Phase 1 (1 trial), Phase 2 (3 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a lung non small cell carcinoma clinical trial?
Eligibility criteria for lung non small cell carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 1
Phase 2 3
Phase 3 2
Top Sponsors
2 trials
2 trials
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT05830058 Phase 2
Recruiting
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Enrollment
32 pts
Location
United States
Sponsor
City of Hope Medical Center
NCT06498635 Phase 3
Recruiting
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Enrollment
306 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT06014827 Phase 2
Recruiting
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
Enrollment
32 pts
Location
United States
Sponsor
City of Hope Medical Center
NCT07323641 Phase 2
Recruiting
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Enrollment
60 pts
Location
United States
Sponsor
Jonsson Comprehensive Cancer C...
NCT07339254
Recruiting
Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study
Enrollment
40 pts
Location
United States
Sponsor
University of Southern Califor...
NCT03819296 Phase 1
Recruiting
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Enrollment
800 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT04267848 Phase 3
Recruiting
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Enrollment
1,210 pts
Location
United States, Guam
Sponsor
National Cancer Institute (NCI...
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology